基于肿瘤负荷与体重指数的阿来替尼治疗ALK阳性NSCLC疗效:ALEX与J-ALEX随机III期试验汇总分析
该研究汇总ALEX和J-ALEX两项III期试验的500例ALK阳性NSCLC患者个体数据,分析肿瘤负荷和体重指数(BMI)对阿来替尼疗效的影响。中位随访17.1个月,阿来替尼较克唑替尼显著改善PFS(HR 0.41,95%CI 0.31-0.55,p<0.001),但OS无显著差异。高肿瘤负荷与更短PFS和OS相关,且肿瘤负荷与治疗存在显著交互作用,低肿瘤负荷者PFS获益更大。BMI>25与更长OS相关,但与PFS无关。
要点
- 阿来替尼一线治疗ALK阳性NSCLC显著改善PFS,但OS未获益。
- 高肿瘤负荷是预后不良因素,且预测阿来替尼PFS获益幅度较小。
- BMI>25 kg/m2与更长OS相关,但与PFS无关,无BMI-治疗交互作用。
核心结论
- 肿瘤负荷在ALK阳性NSCLC中具有预后和预测价值,高肿瘤负荷患者可能从治疗强化中获益。
研究设计与样本
- 研究为ALEX(NCT02075840)和J-ALEX(JapicCTI-132316)两项随机III期试验的个体患者水平汇总分析,共纳入500例患者(阿来替尼组249例,克唑替尼组251例)。
- 主要终点为PFS,采用多因素Cox和随机效应模型分析,基线特征包括高/低肿瘤负荷(RECIST v1.1靶病灶总和高于/低于中位数)和BMI。
主要发现
- 中位随访17.1个月,阿来替尼较克唑替尼改善PFS(HR 0.41,95%CI 0.31-0.55,p<0.001),但OS无显著差异(HR 0.80,95%CI 0.50-1.28,p=0.353)。
- 全人群中,高肿瘤负荷与更短PFS(HR 1.88,95%CI 1.44-2.45,log-rank p<0.001)和OS(HR 2.24,95%CI 1.40-3.58,log-rank p<0.001)相关,多因素分析证实PFS(HR 1.66,95%CI 1.26-2.20,p<0.001)。
- PFS Cox模型中治疗与肿瘤负荷存在显著交互作用(交互p=0.002),阿来替尼vs克唑替尼的PFS获益在低肿瘤负荷(HR 0.25,95%CI 0.16-0.41,p<0.001)优于高肿瘤负荷(HR 0.52,95%CI 0.36-0.76,p=0.001)。
- 多因素分析中,BMI>25 kg/m2(n=144)与PFS无关(HR 0.92,95%CI 0.68-1.25,p=0.375),但与更长OS相关(HR 0.50,95%CI 0.29-0.88,p=0.025);未观察到BMI与治疗的显著交互作用。
临床怎么用
- 对于ALK阳性NSCLC一线治疗,应评估肿瘤负荷,高肿瘤负荷患者预后较差且阿来替尼PFS获益相对较小,可考虑治疗强化策略。
- BMI>25 kg/m2与更长OS相关,但不应据此调整阿来替尼治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although first-line alectinib is highly effective, outcomes in ALK-positive NSCLC remain variable. METHODS: We conducted an individual patient-level pooled analysis of the phase III ALEX (NCT02075840) and J-ALEX (JapicCTI-132316) trials to explore new prognostic and predictive factors. The primary endpoint was PFS. Multivariate Cox and random effects models accounted for trials independence. Baseline characteristics analyzed included high vs. low tumor burden (sum of target lesions by RECIST v1.1 above/below the median) and body mass index (BMI). RESULTS: 500 patients were included (alectinib n = 249, crizotinib n = 251). Baseline characteristics were balanced between the two arms. Median follow-up was 17.1months. Alectinib compared to crizotinib improved PFS (HR 0.41, 95%CI 0.31-0.55, p < 0.001) but not OS (HR 0.80, 95%CI 0.50-1.28, p = 0.353). In the whole population, high tumor burden correlated with shorter PFS (HR 1.88, 95%CI 1.44-2.45, log-rank p < 0.001) and OS (HR 2.24, 95%CI 1.40-3.58, log-rank p < 0.001), confirmed in multivariate analysis (PFS HR 1.66, 95%CI 1.26-2.20, p < 0.001). Significant interaction was found between treatment and tumor burden in PFS cox model (p for interaction=0.002). The PFS benefit of alectinib vs. crizotinib was greater in low tumor burden (HR 0.25, 95%CI 0.16-0.41, p < 0.001) than in high tumor burden (HR 0.52, 95%CI 0.36-0.76, p = 0.001). In multivariate analysis, BMI> 25 kg/m2 (n = 144) did not correlate with PFS (HR 0.92, 95%CI 0.68-1.25, p = 0.375) but was associated with longer OS (HR 0.50, 95%CI 0.29-0.88, p = 0.025). No significant BMI-treatment interaction was observed. CONCLUSIONS: Tumor burden was prognostic and predictive in ALK-positive NSCLC. Treatment intensification may benefit patients with high tumor burden.
引用
- Tagliamento M, Bruzzone M, Blondeaux E, et al. Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEX. Eur J Cancer. 2026. PMID: 42269244. doi:10.1016/j.ejca.2026.116867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。